Ignite Creation Date:
2025-12-25 @ 12:03 AM
Ignite Modification Date:
2026-02-25 @ 12:55 AM
Study NCT ID:
NCT03796858
Status:
COMPLETED
Last Update Posted:
2025-02-03
First Post:
2019-01-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Austria']}, 'conditionBrowseModule': {'meshes': [{'id': 'D015535', 'term': 'Arthritis, Psoriatic'}], 'ancestors': [{'id': 'D025242', 'term': 'Spondylarthropathies'}, {'id': 'D025241', 'term': 'Spondylarthritis'}, {'id': 'D013166', 'term': 'Spondylitis'}, {'id': 'D013122', 'term': 'Spinal Diseases'}, {'id': 'D001847', 'term': 'Bone Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D011565', 'term': 'Psoriasis'}, {'id': 'D017444', 'term': 'Skin Diseases, Papulosquamous'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000588857', 'term': 'guselkumab'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 285}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2019-03-22', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-01', 'completionDateStruct': {'date': '2020-11-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-01-31', 'studyFirstSubmitDate': '2019-01-07', 'studyFirstSubmitQcDate': '2019-01-07', 'lastUpdatePostDateStruct': {'date': '2025-02-03', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-01-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-11-11', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants who Achieve an American College of Rheumatology (ACR) 20 Response at Week 24', 'timeFrame': 'Week 24', 'description': "The ACR 20 Response is defined as greater than or equal to (\\>=) 20 percent (%) improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \\>=20 percent improvement in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS; 0-10 millimeter \\[mm\\], 0 mm=no pain and 10 mm=worst possible pain), participant's global assessment of disease activity by using VAS (scale ranges from 0 mm to 100 mm, \\[0 mm=no pain to 100 mm=worst possible pain\\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and C-reactive protein (CRP)."}], 'secondaryOutcomes': [{'measure': 'Change from Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24', 'timeFrame': 'Baseline, Week 24', 'description': 'The HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping and activities of daily living). Responses in each functional area are scored from 0 to 3 (0=no difficulty and 3=inability to perform a task in that area). Overall score is computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.'}, {'measure': 'Percentage of Participants who Achieve an ACR 50 Response at Week 24', 'timeFrame': 'Week 24', 'description': "The ACR 50 Response is defined as greater than or equal to (\\>=) 50 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \\>=50 percent improvement in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS; 0-10 millimeter \\[mm\\], 0 mm=no pain and 10 mm=worst possible pain), participant's global assessment of disease activity by using VAS (scale ranges from 0 mm to 100 mm, \\[0 mm=no pain to 100 mm=worst possible pain\\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and C-reactive protein (CRP)."}, {'measure': 'Change from Baseline in 36-Item Short form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24', 'timeFrame': 'Baseline, Week 24', 'description': "The SF-36 is a generic health survey with 36 items that measure functional health and well-being from the participant's perspective. The survey is summarized into 8 dimensions/scales: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH). The physical component summary measure is derived from 4 of the 8 health dimensions (aggregate of PF, RP, BP, and GH scales). The minimum score is 0 and the maximum score is 100. A higher score indicates a better health state."}, {'measure': "Percentage of Participants who Achieve Psoriatic Area and Severity Index (PASI) 100 Response at Week 24 Among Participants with >=3% body Surface area Psoriatic Involvement and an Investigator's Global Assessment (IGA) Score of >=2 (Mild) at Baseline", 'timeFrame': 'Week 24', 'description': 'PASI 100 response is defined as 100% improvement in PASI score from baseline (PASI score of 0). The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI scoring system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Arthritis, Psoriatic']}, 'referencesModule': {'references': [{'pmid': '41396391', 'type': 'DERIVED', 'citation': 'Gladman DD, Eder L, Selmi C, Mease PJ, Ogdie A, Lozenski K, Adamson E, Sharaf M, Rampakakis E, Pina Vegas L, Coates LC. Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials. Rheumatol Ther. 2025 Dec 15. doi: 10.1007/s40744-025-00812-3. Online ahead of print.'}, {'pmid': '38488975', 'type': 'DERIVED', 'citation': 'Warren RB, McInnes IB, Nash P, Grouin JM, Lyris N, Willems D, Taieb V, Eells J, Mease PJ. Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatol Ther. 2024 Jun;11(3):829-839. doi: 10.1007/s40744-024-00659-0. Epub 2024 Mar 15.'}, {'pmid': '37906417', 'type': 'DERIVED', 'citation': 'Strober B, Coates LC, Lebwohl MG, Deodhar A, Leibowitz E, Rowland K, Kollmeier AP, Miller M, Wang Y, Li S, Chakravarty SD, Chan D, Shawi M, Yang YW, Thaҫi D, Rahman P. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis. Drug Saf. 2024 Jan;47(1):39-57. doi: 10.1007/s40264-023-01361-w. Epub 2023 Oct 31.'}, {'pmid': '37587493', 'type': 'DERIVED', 'citation': 'Schett G, Chen W, Gao S, Chakravarty SD, Shawi M, Lavie F, Zimmermann M, Sharaf M, Coates LC, Siebert S. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study. Arthritis Res Ther. 2023 Aug 16;25(1):150. doi: 10.1186/s13075-023-03125-4.'}, {'pmid': '36642439', 'type': 'DERIVED', 'citation': 'Rahman P, Boehncke WH, Mease PJ, Gottlieb AB, McInnes IB, Shawi M, Wang Y, Sheng S, Kollmeier AP, Theander E, Yu J, Leibowitz E, Marrache AM, Coates LC. Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis. J Rheumatol. 2023 Jun;50(6):769-780. doi: 10.3899/jrheum.220928. Epub 2023 Jan 15.'}, {'pmid': '34819273', 'type': 'DERIVED', 'citation': 'Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar CS, Shawi M, Noel W, Schett G, McInnes IB. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022 Mar;81(3):359-369. doi: 10.1136/annrheumdis-2021-220991. Epub 2021 Nov 24.'}], 'seeAlsoLinks': [{'url': 'https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003214-41/results', 'label': 'Link to results on EudraCT registry.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate guselkumab efficacy versus placebo in participants with active psoriatic arthritis (PsA) and an inadequate response to Anti-Tumor Necrosis Factor Alpha (TNF-alpha) therapy by assessing the reduction in signs and symptoms of joint disease.', 'detailedDescription': 'Psoriatic arthritis is a multi-faceted disease that impacts the joints, soft tissues, and skin, all of which not only results in functional disability and impaired quality of life, but participants with this disease also have increased mortality. Guselkumab is a monoclonal antibody that binds to human interleukin 23 (IL-23) and inhibits IL-23 specific intracellular signaling and subsequent activation and cytokine production. Investigation of guselkumab in this Phase 3b PsA clinical study is supported by the favorable efficacy and safety results from Phase 2 study of guselkumab in PsA and Phase 2 and Phase 3 studies in psoriasis including the subset of participants with PsA. The primary hypothesis is that guselkumab 100 milligram (mg) at Weeks 0, 4, and every 8 weeks (q8w) thereafter is superior to placebo which will be assessed by the proportion of participants achieving an American College of Rheumatology (ACR 20) response at Week 24. The study includes 2 periods: A 24-week double-blind, placebo-controlled period for the primary analysis of the efficacy and safety of guselkumab, compared with placebo and a 32-week active-treatment and safety follow-up period for additional analysis of the efficacy and safety of guselkumab. Safety will be monitored throughout the study (Up to Week 56).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Have a diagnosis of psoriatic arthritis (PsA) for at least 6 months before the first administration of study intervention and meet classification criteria for Psoriatic Arthritis (CASPAR) at screening\n* Have active PsA as defined by at least 3 swollen joints and at least 3 tender joints at screening and at baseline\n* Have at least 1 of the PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis\n* Have an inadequate response to anti-TNF alpha therapy, defined as presence of active PsA despite previous treatment with either 1 or 2 anti-TNF alpha agents and either of the following: a) Lack of benefit of an anti-TNF alpha therapy, as documented in the participant history by the treating physician, after at least 12 weeks of etanercept, adalimumab, golimumab, or certolizumab pegol therapy (or biosimilars) and/or at least a 14-week dosage regimen (i.e., at least 4 doses) of infliximab (or biosimilars). Documented lack of benefit may include inadequate improvement in joint counts, skin response, physical function, or disease activity, b) Intolerance to an anti-TNF alpha therapy, as documented in the patient history by the treating physician, to etanercept, adalimumab, golimumab, certolizumab pegol, or infliximab (or biosimilars, if available)\n* Be willing to refrain from the use of complementary therapies for PsA or psoriasis including ayurvedic medicine, traditional Taiwanese, Korean, or Chinese medications and acupuncture within 2 weeks before the first study intervention administration and through Week 48\n\nExclusion Criteria:\n\n* Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy, including but not limited to rheumatoid arthritis (RA), axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, or Lyme disease\n* Has ever received more than 2 different anti-TNF alpha agents\n* Has previously received any biologic treatment (other than anti-TNF Alpha agents), including, but not limited to ustekinumab, abatacept, secukinumab, tildrakizumab, ixekizumab, brodalumab, risankizumab, or other investigative biologic treatment\n* Has previously received tofacitinib, baricitinib, filgotinib, peficitinib (ASP015K), decernotinib (VX 509), or any other a Janus kinase (JAK) inhibitor\n* Has previously received any systemic immunosuppressants (for example, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention'}, 'identificationModule': {'nctId': 'NCT03796858', 'acronym': 'COSMOS', 'briefTitle': 'A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy', 'organization': {'class': 'INDUSTRY', 'fullName': 'Janssen Pharmaceutica N.V., Belgium'}, 'officialTitle': 'Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNFα) Therapy', 'orgStudyIdInfo': {'id': 'CR108573'}, 'secondaryIdInfos': [{'id': '2018-003214-41', 'type': 'EUDRACT_NUMBER'}, {'id': 'CNTO1959PSA3003', 'type': 'OTHER', 'domain': 'Janssen Pharmaceutica N.V., Belgium'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Group 1: Guselkumab', 'description': 'Participants will receive guselkumab 100 milligram (mg) Subcutaneous (SC) injection at Weeks 0, 4, 12, 20, 28, 36, and 44 and placebo SC at Week 24 to maintain the blind. At Week 16, Participants who meet the early escape criteria will receive placebo at Week 16 and guselkumab at Week 20, then guselkumab every 8 weeks (q8w).', 'interventionNames': ['Drug: Guselkumab 100 mg', 'Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Group 2: Placebo followed by Guselkumab', 'description': 'Participants will receive placebo SC injection at Weeks 0, 4, 12, and 20, and will crossover to receive guselkumab 100 mg SC injection at Weeks 24, 28, 36, and 44. At Week 16, Participants who meet the early escape criteria will receive guselkumab at Weeks 16 and 20, then guselkumab q8w.', 'interventionNames': ['Drug: Guselkumab 100 mg', 'Drug: Placebo']}], 'interventions': [{'name': 'Guselkumab 100 mg', 'type': 'DRUG', 'otherNames': ['CNTO 1959'], 'description': 'Participants will receive guselkumab 100mg as SC injection.', 'armGroupLabels': ['Group 1: Guselkumab', 'Group 2: Placebo followed by Guselkumab']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Participants will receive placebo as SC injection.', 'armGroupLabels': ['Group 1: Guselkumab', 'Group 2: Placebo followed by Guselkumab']}]}, 'contactsLocationsModule': {'locations': [{'zip': '1000', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'CHU Saint Pierre BXL', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '3600', 'city': 'Genk', 'country': 'Belgium', 'facility': 'Reuma Clinic', 'geoPoint': {'lat': 50.965, 'lon': 5.50082}}, {'zip': '9000', 'city': 'Ghent', 'country': 'Belgium', 'facility': 'Universitair Ziekenhuis Gent', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'zip': '3000', 'city': 'Leuven', 'country': 'Belgium', 'facility': 'UZ Leuven', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'zip': '5800', 'city': 'Pleven', 'country': 'Bulgaria', 'facility': 'Diagnostic - Consulting Center II-Pleven', 'geoPoint': {'lat': 43.41791, 'lon': 24.61666}}, {'zip': '5800', 'city': 'Pleven', 'country': 'Bulgaria', 'facility': 'Medical Center Medconsult-Pleven', 'geoPoint': {'lat': 43.41791, 'lon': 24.61666}}, {'zip': '4003', 'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'Multiprofile Hospital for Active Treatment Plovdiv', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '4004', 'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'Multiprofile Hosptal for Active Treatment Eurohospital Plovdiv', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '7003', 'city': 'Rousse', 'country': 'Bulgaria', 'facility': 'Medical Center Teodora', 'geoPoint': {'lat': 43.84872, 'lon': 25.9534}}, {'zip': '1505', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Diagnostic Consulting Center No 17', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1606', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Military Medical Academy', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '33076', 'city': 'Bordeaux', 'country': 'France', 'facility': 'Hopital Pellegrin Tripode - CHU de Bordeaux', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'zip': '34295', 'city': 'Montpellier', 'country': 'France', 'facility': 'CHU Lapeyronie', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'zip': '45067', 'city': 'Orléans', 'country': 'France', 'facility': "Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source", 'geoPoint': {'lat': 47.90248, 'lon': 1.90407}}, {'zip': '75010', 'city': 'Paris', 'country': 'France', 'facility': 'Hopital Lariboisiere', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75013', 'city': 'Paris', 'country': 'France', 'facility': 'Hôpital Pitié-Salpétrière', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75014', 'city': 'Paris', 'country': 'France', 'facility': 'Hopital Cochin', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '30159', 'city': 'Toulouse', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Toulouse - Hopital Purpan', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'zip': '37044', 'city': 'Tours', 'country': 'France', 'facility': 'CHU Trousseau - Service de Rhumatologie', 'geoPoint': {'lat': 47.39484, 'lon': 0.70398}}, {'zip': '40225', 'city': 'Düsseldorf', 'country': 'Germany', 'facility': 'Universitatsklinikum Dusseldorf', 'geoPoint': {'lat': 51.22172, 'lon': 6.77616}}, {'zip': '20095', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Hamburger Rheuma Forschungszentrum II', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '30625', 'city': 'Hanover', 'country': 'Germany', 'facility': 'Medizinische Hochschule Hannover', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'zip': '44649', 'city': 'Herne', 'country': 'Germany', 'facility': 'Rheumazentrum Ruhrgebiet', 'geoPoint': {'lat': 51.5388, 'lon': 7.22572}}, {'zip': '24768', 'city': 'Rendsburg', 'country': 'Germany', 'facility': 'Rheumatologische Schwerpunktpraxis', 'geoPoint': {'lat': 54.30182, 'lon': 9.67175}}, {'zip': '42105', 'city': 'Wuppertal', 'country': 'Germany', 'facility': 'Krankenhaus St. Josef', 'geoPoint': {'lat': 51.25627, 'lon': 7.14816}}, {'zip': '56429', 'city': 'Thessaloniki', 'country': 'Greece', 'facility': '424 Military Hospital of Thessaloniki', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'zip': '1023', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Betegapolo Irgalmas Rend Budai Irgalmasrendi Korhaz', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '5700', 'city': 'Gyula', 'country': 'Hungary', 'facility': 'Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz', 'geoPoint': {'lat': 46.65, 'lon': 21.28333}}, {'zip': '4400', 'city': 'Nyíregyháza', 'country': 'Hungary', 'facility': 'Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz', 'geoPoint': {'lat': 47.95539, 'lon': 21.71671}}, {'zip': '8000', 'city': 'Székesfehérvár', 'country': 'Hungary', 'facility': 'Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz', 'geoPoint': {'lat': 47.18995, 'lon': 18.41034}}, {'zip': '5000', 'city': 'Szolnok', 'country': 'Hungary', 'facility': 'MAV Korhaz es Rendelointezet', 'geoPoint': {'lat': 47.18066, 'lon': 20.19835}}, {'zip': '8200', 'city': 'Veszprém', 'country': 'Hungary', 'facility': 'Vital Medical Center Orvosi es Fogaszati Kozpont', 'geoPoint': {'lat': 47.09327, 'lon': 17.91149}}, {'zip': '7830604', 'city': 'Ashkelon', 'country': 'Israel', 'facility': 'Barzilai Medical Center', 'geoPoint': {'lat': 31.66926, 'lon': 34.57149}}, {'zip': '31048', 'city': 'Haifa', 'country': 'Israel', 'facility': 'Bnai Zion Medical Center', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '34362', 'city': 'Haifa', 'country': 'Israel', 'facility': 'Carmel Medical Center', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '91120', 'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Hadassah Medical Center', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '5265601', 'city': 'Ramat Gan', 'country': 'Israel', 'facility': 'Sheba Medical Center', 'geoPoint': {'lat': 32.08227, 'lon': 34.81065}}, {'zip': '64239', 'city': 'Tel Aviv', 'country': 'Israel', 'facility': 'Tel Aviv Sourasky Medical Center', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'zip': '80131', 'city': 'Napoli', 'country': 'Italy', 'facility': 'Azienda Ospedaliera Universitaria Federico II', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'zip': '90127', 'city': 'Palermo', 'country': 'Italy', 'facility': 'Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone', 'geoPoint': {'lat': 38.1166, 'lon': 13.3636}}, {'zip': '00133', 'city': 'Roma', 'country': 'Italy', 'facility': 'Policlinico Tor Vergata', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'zip': '00168', 'city': 'Rome', 'country': 'Italy', 'facility': 'Complesso Integrato Columbus', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '20089', 'city': 'Rozzano (MI)', 'country': 'Italy', 'facility': 'Humanitas Hospital', 'geoPoint': {'lat': 45.38193, 'lon': 9.1559}}, {'zip': '85 168', 'city': 'Bydgoszcz', 'country': 'Poland', 'facility': 'Szpital Uniwersytecki Nr 2 w Bydgoszczy', 'geoPoint': {'lat': 53.1235, 'lon': 18.00762}}, {'zip': '82-300', 'city': 'Elblag', 'country': 'Poland', 'facility': 'Centrum Kliniczno Badawcze', 'geoPoint': {'lat': 54.1522, 'lon': 19.40884}}, {'zip': '90 265', 'city': 'Lodz', 'country': 'Poland', 'facility': 'Dermed Centrum Medyczne Sp z o o', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '90-242', 'city': 'Lodz', 'country': 'Poland', 'facility': 'Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '05 830', 'city': 'Nadarzyn', 'country': 'Poland', 'facility': 'NZOZ Lecznica MAK MED S C', 'geoPoint': {'lat': 52.09438, 'lon': 20.80776}}, {'zip': '00-874', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Medycyna Kliniczna', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '04-030', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Mazowieckie Centrum Reumatologii i Osteoporozy', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '51 685', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'WroMedica I Bielicka A Strzalkowska s c', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '2805 267', 'city': 'Almada', 'country': 'Portugal', 'facility': 'Uls Almada Seixal - Hosp. Garcia de Orta', 'geoPoint': {'lat': 38.67902, 'lon': -9.1569}}, {'zip': '3814-501', 'city': 'Aveiro', 'country': 'Portugal', 'facility': 'Uls Regiao Aveiro - Hosp. Infante D. Pedro', 'geoPoint': {'lat': 40.64575, 'lon': -8.64643}}, {'zip': '4710 243', 'city': 'Braga', 'country': 'Portugal', 'facility': 'Uls Braga - Hosp. Braga', 'geoPoint': {'lat': 41.5514, 'lon': -8.42311}}, {'zip': '1050 034', 'city': 'Lisbon', 'country': 'Portugal', 'facility': 'Ipr Inst Port de Reumatologia', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '1349 019', 'city': 'Lisbon', 'country': 'Portugal', 'facility': 'Uls Lisboa Ocidental - Hosp. Egas Moniz', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '1649 035', 'city': 'Lisbon', 'country': 'Portugal', 'facility': 'Uls Santa Maria - Hosp. Santa Maria', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '4990-041', 'city': 'Ponte de Lima', 'country': 'Portugal', 'facility': 'Ulsam - Hosp. Conde de Bertiandos', 'geoPoint': {'lat': 41.76719, 'lon': -8.58393}}, {'zip': '454076', 'city': 'Chelyabinsk', 'country': 'Russia', 'facility': 'Chelyabinck Regional Clinical Hospital', 'geoPoint': {'lat': 55.1611, 'lon': 61.42877}}, {'zip': '650000', 'city': 'Kemerovo', 'country': 'Russia', 'facility': 'Kemerovo State Medical University', 'geoPoint': {'lat': 55.35417, 'lon': 86.10435}}, {'zip': '650066', 'city': 'Kemerovo', 'country': 'Russia', 'facility': 'Medical Centre Maximum Health', 'geoPoint': {'lat': 55.35417, 'lon': 86.10435}}, {'zip': '141060', 'city': 'Korolyov', 'country': 'Russia', 'facility': 'Family polyclinic #4', 'geoPoint': {'lat': 55.91417, 'lon': 37.82556}}, {'zip': '350020', 'city': 'Krasnodar', 'country': 'Russia', 'facility': 'Krasnodar Clinical Dermatovenerologic Dispensary', 'geoPoint': {'lat': 45.04534, 'lon': 38.98178}}, {'zip': '660022', 'city': 'Krasnoyarsk', 'country': 'Russia', 'facility': 'Krasnoyarsk State Medical University', 'geoPoint': {'lat': 56.03742, 'lon': 92.93136}}, {'zip': '460000', 'city': 'Orenburg', 'country': 'Russia', 'facility': 'Orenburg State Medical Academy', 'geoPoint': {'lat': 51.76712, 'lon': 55.09883}}, {'zip': '344007', 'city': 'Rostov', 'country': 'Russia', 'facility': 'Rostov Regional Clinical Dermatovenerological Dispensary', 'geoPoint': {'lat': 57.19081, 'lon': 39.41307}}, {'zip': '390046', 'city': 'Ryazan', 'country': 'Russia', 'facility': 'Ryazan Regional Clinical Dermatovenerological Dispensary', 'geoPoint': {'lat': 54.62696, 'lon': 39.70415}}, {'zip': '194291', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Leningrad region clinical hospital', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '443095', 'city': 'Samara', 'country': 'Russia', 'facility': 'Samara Regional Clinical Hospital Named After V.D.Seredavin', 'geoPoint': {'lat': 53.20767, 'lon': 50.13553}}, {'zip': '410053', 'city': 'Saratov', 'country': 'Russia', 'facility': 'Sararov Regional Clinical Hospital', 'geoPoint': {'lat': 51.54048, 'lon': 45.9901}}, {'zip': '214025', 'city': 'Smolensk', 'country': 'Russia', 'facility': 'Smolensk regional hospital on Smolensk railway station', 'geoPoint': {'lat': 54.77826, 'lon': 32.05088}}, {'zip': '300053', 'city': 'Tula', 'country': 'Russia', 'facility': 'Tula Regional Clinical Dermatovenerological Dispensary', 'geoPoint': {'lat': 54.19609, 'lon': 37.61822}}, {'zip': '450005', 'city': 'Ufa', 'country': 'Russia', 'facility': 'Republican Clinical Hospital - G.G. Kuvatov', 'geoPoint': {'lat': 54.74306, 'lon': 55.96779}}, {'zip': '432063', 'city': 'Ulyanovsk', 'country': 'Russia', 'facility': 'Ulyanovsk Regional Clinical Hospital', 'geoPoint': {'lat': 54.32824, 'lon': 48.38657}}, {'zip': '173008', 'city': 'Veliky Novgorod', 'country': 'Russia', 'facility': 'Regional Clinical Hospital', 'geoPoint': {'lat': 58.52131, 'lon': 31.27104}}, {'zip': '150003', 'city': 'Yaroslavl', 'country': 'Russia', 'facility': 'Clinical Emergency Hospital n.a. N.V. Solovyev', 'geoPoint': {'lat': 57.62987, 'lon': 39.87368}}, {'zip': '150007', 'city': 'Yaroslavl', 'country': 'Russia', 'facility': 'Clinical Hospital #3', 'geoPoint': {'lat': 57.62987, 'lon': 39.87368}}, {'zip': '15006', 'city': 'A Coruña', 'country': 'Spain', 'facility': 'Hosp Univ A Coruna', 'geoPoint': {'lat': 43.37135, 'lon': -8.396}}, {'zip': '48902', 'city': 'Barakaldo', 'country': 'Spain', 'facility': 'Hosp. Univ. de Cruces', 'geoPoint': {'lat': 43.29639, 'lon': -2.98813}}, {'zip': '08916', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hosp. Univ. Germans Trias I Pujol', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '48013', 'city': 'Bilbao', 'country': 'Spain', 'facility': 'Hosp. Univ. de Basurto', 'geoPoint': {'lat': 43.26271, 'lon': -2.92528}}, {'zip': '14004', 'city': 'Córdoba', 'country': 'Spain', 'facility': 'Hosp Reina Sofia', 'geoPoint': {'lat': 37.89155, 'lon': -4.77275}}, {'zip': '28034', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hosp. Univ. Ramon Y Cajal', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28041', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hosp. Univ. 12 de Octubre', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28905', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hosp. Univ. de Getafe', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '29009', 'city': 'Málaga', 'country': 'Spain', 'facility': 'Hosp Regional Univ de Malaga', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'zip': '15706', 'city': 'Santiago de Compostela', 'country': 'Spain', 'facility': 'Hosp. Clinico Univ. de Santiago', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'zip': '41009', 'city': 'Seville', 'country': 'Spain', 'facility': 'Hosp. Virgen Macarena', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '41010', 'city': 'Seville', 'country': 'Spain', 'facility': 'Hosp. Infanta Luisa', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '41013', 'city': 'Seville', 'country': 'Spain', 'facility': 'Hosp. Virgen Del Rocio', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '41014', 'city': 'Seville', 'country': 'Spain', 'facility': 'Hosp. Ntra. Sra. de Valme', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '36312', 'city': 'Vigo', 'country': 'Spain', 'facility': 'Hosp. Do Meixoeiro', 'geoPoint': {'lat': 42.23282, 'lon': -8.72264}}, {'zip': '18009', 'city': 'Cherkasy', 'country': 'Ukraine', 'facility': 'Communal Noncommercial Enterprise Cherkasy Regional Hospital of Cherkasy Regional Council', 'geoPoint': {'lat': 49.44452, 'lon': 32.05738}}, {'zip': '76018', 'city': 'Ivano-Frankivsk', 'country': 'Ukraine', 'facility': 'Ivano-Frankivsk National Medical University, Ivano-Frankivsk City Clinical Hospital', 'geoPoint': {'lat': 48.92312, 'lon': 24.71248}}, {'zip': '61029', 'city': 'Kharkiv', 'country': 'Ukraine', 'facility': 'City Multifield Hospital #18, Mechnikov Institute of Microbiology and Immunology of NAMS', 'geoPoint': {'lat': 49.98177, 'lon': 36.25475}}, {'zip': '61058', 'city': 'Kharkiv', 'country': 'Ukraine', 'facility': 'Municipal non-commercial enterprise of Kharkiv Regional Council Regional Clinical Hospital', 'geoPoint': {'lat': 49.98177, 'lon': 36.25475}}, {'zip': '29000', 'city': 'Khmelnytsky', 'country': 'Ukraine', 'facility': 'Khmelnitckiy regional hospital'}, {'zip': '02125', 'city': 'Kyiv', 'country': 'Ukraine', 'facility': 'Kyiv City Clinical Hospital #3, National Medical University', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '04050', 'city': 'Kyiv', 'country': 'Ukraine', 'facility': "Medical Center 'Consylium Medical'", 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'city': 'Kyiv', 'country': 'Ukraine', 'facility': 'Kyiv Railway Station Clinical Hospital #2', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'city': 'Kyiv', 'country': 'Ukraine', 'facility': 'SI National Scientific Center Institute of Cardiology of M.D. Strazhesko of NAMS of Ukraine', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '36011', 'city': 'Poltava', 'country': 'Ukraine', 'facility': 'ME Poltava Regional Clinical Hospital named after M.V. Sklifosovsky of Poltava Regional Consuil', 'geoPoint': {'lat': 49.58925, 'lon': 34.55367}}, {'zip': '40031', 'city': 'Sumy', 'country': 'Ukraine', 'facility': 'Municipal Institution of Sumy Regional Council Sumy Regional Clinical Hospital', 'geoPoint': {'lat': 50.91741, 'lon': 34.79906}}, {'zip': '46002', 'city': 'Ternopil', 'country': 'Ukraine', 'facility': 'Municipal Non-commercial Enterprise Ternopil University Hospital of Ternopil Regional Council', 'geoPoint': {'lat': 49.55404, 'lon': 25.59067}}, {'zip': '21009', 'city': 'Vinnytsia', 'country': 'Ukraine', 'facility': 'Medical Center LTD Health Clinic Department of Cardiology and Rheumatology', 'geoPoint': {'lat': 49.2322, 'lon': 28.46871}}, {'zip': '21018', 'city': 'Vinnytsia', 'country': 'Ukraine', 'facility': 'VNMUn.af.Pyrogova,CNE Vinnytsia Regional Clinical Hospital n.af.Pyrogova Vinnytsia Regional Council', 'geoPoint': {'lat': 49.2322, 'lon': 28.46871}}, {'zip': '10002', 'city': 'Zhytomyr', 'country': 'Ukraine', 'facility': 'Municipal institution Central Clinical Hospital #1 Zhytomir', 'geoPoint': {'lat': 50.26235, 'lon': 28.67913}}, {'zip': 'BA1 1RL', 'city': 'Bath', 'country': 'United Kingdom', 'facility': 'Royal National Hospital for Rheumatic Diseases', 'geoPoint': {'lat': 51.3751, 'lon': -2.36172}}, {'zip': 'CB2 0QQ', 'city': 'Cambridge', 'country': 'United Kingdom', 'facility': 'Cambridge University Hospitals NHS Foundation Trust', 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'zip': 'WS11 5XY', 'city': 'Cannock', 'country': 'United Kingdom', 'facility': 'Cannock Chase Hospital', 'geoPoint': {'lat': 52.69045, 'lon': -2.03085}}, {'zip': 'LS7 4SA', 'city': 'Leeds', 'country': 'United Kingdom', 'facility': 'Chapel Allerton Hospital', 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'zip': 'E11 1NR', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Barts Health NHS Trust Whipps Cross University Hospital NHS Trust', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SE1 9RS', 'city': 'London', 'country': 'United Kingdom', 'facility': "Guy's and St Thomas' NHS Foundation Trust - Rheumatoid Arthritis (RA) Clinic", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'NE29 8NH', 'city': 'Newcastle', 'country': 'United Kingdom', 'facility': 'North Tyneside General Hospital', 'geoPoint': {'lat': 54.21804, 'lon': -5.88979}}, {'zip': 'PE3 9GZ', 'city': 'Peterborough', 'country': 'United Kingdom', 'facility': 'Peterborough City Hospital', 'geoPoint': {'lat': 52.57364, 'lon': -0.24777}}, {'zip': 'ST6 7AG', 'city': 'Stoke-on-Trent', 'country': 'United Kingdom', 'facility': 'Haywood Hospital', 'geoPoint': {'lat': 53.00415, 'lon': -2.18538}}, {'zip': 'TQ2 7AA', 'city': 'Torquay', 'country': 'United Kingdom', 'facility': 'Torbay Hospital-Devon', 'geoPoint': {'lat': 50.46198, 'lon': -3.52522}}], 'overallOfficials': [{'name': 'Janssen Pharmaceutica N.V., Belgium Clinical Trial', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Janssen Pharmaceutica N.V., Belgium'}]}, 'ipdSharingStatementModule': {'url': 'https://www.janssen.com/clinical-trials/transparency', 'ipdSharing': 'YES', 'description': 'The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials\\\\transparency.\n\nAs noted on this site, requests for access to the study data can be submitted through Yale open Access (YODA) Project site at yoda.yale.edu'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Janssen Pharmaceutica N.V., Belgium', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}